Catalent’s stock down after Sarepta’s PhIII Duchenne study misses primary endpoint

Catal­ent’s stock $CTLT has dropped by as much as 17% to $33 on the Nas­daq af­ter Sarep­ta an­nounced on Mon­day that its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py did not suc­ceed in the pri­ma­ry end­point of a Phase III study.

On Jan. 5, Catal­ent and Sarep­ta an­nounced that their col­lab­o­ra­tion was ex­pand­ed so that the CD­MO would pro­duce the DMD as­set for com­mer­cial use. On June 22, the gene ther­a­py, mar­ket­ed as Ele­v­idys, re­ceived an ac­cel­er­at­ed ap­proval from the FDA for DMD in boys aged 4 and 5.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.